Health: pharmaceuticals; program for the wholesale importation of pharmaceuticals from Canada; provide for. Creates new act.
SB 317 would create the “Prescription Drug Importation Act” and authorize the Michigan Department of Health and Human Services to develop a wholesale prescription drug importation program. The program would allow the state to contract with a licensed drug wholesaler to seek federal certification to import prescription drugs from a Canadian supplier, subject to federal law and a series of safety, tracking, and cost-savings requirements. Only drugs meeting FDA safety and effectiveness standards could be imported, and the program would be limited to drugs expected to produce significant savings for Michigan consumers.
The bill also requires the department to seek federal approval or waivers needed to allow participation by entities in the federal 340B drug pricing program without jeopardizing that status. If implemented, the department would create a registration process for participating insurers, pharmacies, and providers, publish wholesale acquisition cost information, conduct outreach, and report annually to the Legislature and the public on program participation, prescriptions dispensed, cost savings, and audit findings. The department would also be authorized to adopt rules and to monitor for anticompetitive behavior with the Attorney General’s office.
If enacted, the bill would add a new state framework for importing prescription drugs from Canada and would direct MDHHS to administer, certify, and oversee the program under federal importation rules. It would not itself guarantee importation, but it would establish the legal authority, administrative duties, reporting obligations, and rulemaking power needed for a state-run importation system. The bill would affect drug wholesalers, pharmacies, health insurers, health care providers, consumers, and potentially 340B-covered entities, while also implicating federal patent, drug safety, and supply-chain tracking laws.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears policy-driven and consumer-cost focused, with the bill framed as a mechanism to lower prescription drug prices. The structure of the bill emphasizes safety, federal compliance, and oversight, suggesting an effort to make the proposal more administratively and legally defensible. No direct opposition or support is documented in the provided context, but the inclusion of anticompetitive monitoring and 340B protections indicates awareness of likely stakeholder concerns.
The main points of contention are likely to be federal preemption and compliance, drug safety and traceability, and the impact on existing pharmaceutical market structures. The bill requires federal certification and multiple approvals, waivers, or agreements, which could be a practical hurdle and a legal flashpoint. Another likely issue is whether importing drugs from Canada would meaningfully reduce costs without disrupting supply chains or conflicting with patent and distribution rules. Stakeholders most likely to raise concerns include pharmaceutical manufacturers, wholesalers, and possibly some providers or insurers, while consumer advocates and cost-conscious purchasers would likely support the proposal.